JP2019525898A5 - - Google Patents

Download PDF

Info

Publication number
JP2019525898A5
JP2019525898A5 JP2018564945A JP2018564945A JP2019525898A5 JP 2019525898 A5 JP2019525898 A5 JP 2019525898A5 JP 2018564945 A JP2018564945 A JP 2018564945A JP 2018564945 A JP2018564945 A JP 2018564945A JP 2019525898 A5 JP2019525898 A5 JP 2019525898A5
Authority
JP
Japan
Prior art keywords
cell
polypeptide
hla
composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018564945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019525898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/064323 external-priority patent/WO2017212072A1/en
Publication of JP2019525898A publication Critical patent/JP2019525898A/ja
Publication of JP2019525898A5 publication Critical patent/JP2019525898A5/ja
Ceased legal-status Critical Current

Links

JP2018564945A 2016-06-10 2017-06-12 ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法 Ceased JP2019525898A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16173986 2016-06-10
EP16173986.7 2016-06-10
EP16173970.1 2016-06-10
EP16173970 2016-06-10
PCT/EP2017/064323 WO2017212072A1 (en) 2016-06-10 2017-06-12 Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2019525898A JP2019525898A (ja) 2019-09-12
JP2019525898A5 true JP2019525898A5 (enExample) 2020-07-27

Family

ID=59101448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564945A Ceased JP2019525898A (ja) 2016-06-10 2017-06-12 ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法

Country Status (10)

Country Link
US (5) US11596654B2 (enExample)
EP (4) EP3469362B1 (enExample)
JP (1) JP2019525898A (enExample)
KR (1) KR102489954B1 (enExample)
CN (1) CN109997041B (enExample)
CA (2) CA3027124A1 (enExample)
ES (1) ES2987986T3 (enExample)
HU (1) HUE068936T2 (enExample)
PL (1) PL3469361T3 (enExample)
WO (2) WO2017212072A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6403663B2 (ja) 2012-03-28 2018-10-10 ガデタ・ベー・フェー コンビナトリアルガンマ９デルタ２ｔ細胞レセプター鎖交換
PL3469361T3 (pl) 2016-06-10 2025-02-03 Gadeta B.V. Nowy sposób identyfikacji łańcuchów receptora limfocytu t delta (lub limfocytu t gamma) lub części tych łańcuchów, które pośredniczą w odpowiedzi przeciwnowotworowej lub przeciwzakaźnej
CA3063807A1 (en) 2017-05-18 2018-11-22 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019156566A1 (en) * 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
MX2020011158A (es) * 2018-04-23 2021-01-08 Commscope Technologies Llc Recinto de telecomunicaciones con sistema de bloqueo modular.
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
WO2021236963A1 (en) * 2020-05-20 2021-11-25 Chan Zuckerberg Biohub, Inc. Total rna profiling of biological samples and single cells
WO2022136681A1 (en) 2020-12-23 2022-06-30 Gadeta B.V. Chimeric, transmembrane proteins with bidirectional signalling activity
CN113046320B (zh) * 2021-02-19 2023-04-14 中国医学科学院基础医学研究所 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途
EP4059955A1 (en) 2021-03-19 2022-09-21 Medizinische Hochschule Hannover Hla-dr-specific gamma delta tcr constructs and use thereof
WO2022214707A1 (en) 2021-04-09 2022-10-13 Gadeta B.V. Cellular reporter and methods of using the same
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20260014199A1 (en) 2022-06-17 2026-01-15 Gadeta B.V. Modified immune cells
US20240075068A1 (en) * 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
US20240043496A1 (en) * 2022-07-26 2024-02-08 Gadeta B.V. Delta t-cell or gamma receptor chains or parts thereof for treating ovarian cancer
WO2025231488A1 (en) * 2024-05-03 2025-11-06 Northwestern University Gamma-delta t cell receptors for cancer therapy

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US5962271A (en) 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
EP0981636B1 (en) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
GB9810099D0 (en) * 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
BR9910253A (pt) * 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
DE19909769A1 (de) 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
JP2001332430A (ja) 2000-05-22 2001-11-30 Murata Mfg Co Ltd トランス
WO2002024718A1 (en) 2000-09-19 2002-03-28 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
KR100669065B1 (ko) * 2001-04-03 2007-01-15 다카라 바이오 가부시키가이샤 세포상해성 ｔ 림프구
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003235593A1 (en) 2002-01-10 2003-07-30 National Jewish Medical And Research Center USE OF SOLUBLE GammaDelta T CELL RECEPTORS FOR REGULATING T CELL FUNCTION
AU2003259913A1 (en) 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005051988A2 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2005005631A1 (ja) 2003-07-11 2005-01-20 Dainippon Sumitomo Pharma Co., Ltd. リビン由来のｈｌａ-ａ２４結合性癌抗原ペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050249743A1 (en) * 2004-01-12 2005-11-10 Thierry Boon-Falleur Isolated peptides which bind to HLA-A24 molecules and uses thereof
US20050255105A1 (en) 2004-03-22 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Severe myelin deficits induced by self-reactive gamma delta T cells
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2006026051A2 (en) * 2004-08-03 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
GB0506760D0 (en) * 2005-04-01 2005-05-11 Avidex Ltd High affinity HIV TCRS
EP1941028A2 (en) 2005-08-08 2008-07-09 Fondazione Centro San Raffaele Del Monte Tabor Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes.
EP1806358B1 (en) * 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
EP1945246A4 (en) * 2005-09-22 2009-03-11 Irun R Cohen IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP2288700B1 (en) 2008-05-09 2017-02-08 Agency for Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010087335A1 (ja) 2009-01-27 2010-08-05 学校法人産業医科大学 Ｔ細胞抗原受容体遺伝子、受容体α鎖及びβ鎖発現用ベクター並びに細胞障害性Ｔ細胞
ES2743507T3 (es) 2009-11-02 2020-02-19 Univ Emory Inmunoterapia resistente a fármaco para el tratamiento de un cáncer
CN102453701B (zh) 2010-10-26 2014-08-13 中国医学科学院基础医学研究所 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途
US20150353643A1 (en) 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof
EP2686417B1 (de) 2011-03-17 2016-06-08 Miltenyi Biotec GmbH Tcralpha/beta-depletierte zellpräparationen
CN102532269B (zh) * 2011-05-16 2014-07-09 中国医学科学院基础医学研究所 γδT淋巴细胞中δ1链互补决定域3的优势序列及其TCR受体转染细胞与应用
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
PH12014500247A1 (en) 2011-07-29 2014-03-24 Univ Pennsylvania Switch costimulatory receptors
JP6403663B2 (ja) * 2012-03-28 2018-10-10 ガデタ・ベー・フェー コンビナトリアルガンマ９デルタ２ｔ細胞レセプター鎖交換
EP3763810A3 (en) 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
WO2014179202A1 (en) * 2013-05-02 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
JP6164759B2 (ja) * 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
CN106459915A (zh) 2014-02-04 2017-02-22 凯德药业公司 用于治疗b细胞恶性肿瘤和其它癌症的自体t细胞的生产方法及其组合物
SG11201609370QA (en) * 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
WO2016195086A1 (ja) 2015-06-05 2016-12-08 医療法人社団 滉志会 アレルギー性疾患の治療薬
ES2710618T3 (es) 2015-08-06 2019-04-26 Agency Science Tech & Res Anticuerpos frente a IL2R-Beta/cadena gamma común
AU2016318961A1 (en) 2015-09-11 2018-03-22 Agenus Inc. Engineered host cells and methods of use thereof
CN105296431B (zh) * 2015-11-26 2018-10-09 北京佳德和细胞治疗技术有限公司 肿瘤结合特异性γδTCR基因修饰的αβT细胞及其抑癌用途
US12297427B2 (en) 2015-12-04 2025-05-13 St. Jude Children's Research Hospital, Inc. Cloning and expression system for T-cell receptors
MX2018013864A (es) 2016-05-12 2019-06-10 Adicet Bio Inc Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
US10222369B2 (en) 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
PL3469361T3 (pl) 2016-06-10 2025-02-03 Gadeta B.V. Nowy sposób identyfikacji łańcuchów receptora limfocytu t delta (lub limfocytu t gamma) lub części tych łańcuchów, które pośredniczą w odpowiedzi przeciwnowotworowej lub przeciwzakaźnej
EP3548050A1 (en) 2016-12-02 2019-10-09 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
EP3592839B1 (en) * 2017-03-07 2023-07-05 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
CA3063807A1 (en) 2017-05-18 2018-11-22 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies
WO2019219979A1 (en) 2018-05-18 2019-11-21 Umc Utrecht Holding B.V. Compositions and methods for cell targeting therapies

Similar Documents

Publication Publication Date Title
JP7631485B2 (ja) キメラポックスウイルス組成物及びその使用
De Clercq Mozobil®(Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration
Luo et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Galluzzi et al. Immunological mechanisms underneath the efficacy of cancer therapy
Cheson et al. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel–an update
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
Fan et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
JP2019530713A5 (enExample)
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
JP2014076062A5 (enExample)
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
JP2016513640A5 (enExample)
Bidier et al. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes
JP2016530280A5 (enExample)
JP2018509163A5 (enExample)
WO2008016431A3 (en) Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
JP2020510704A5 (enExample)
JP2018503644A5 (enExample)
Ziffels et al. Antibody-based delivery of cytokine payloads to carbonic anhydrase IX leads to cancer cures in immunocompetent tumor-bearing mice
RU2018101722A (ru) Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
Amin et al. Immunoediting dynamics in glioblastoma: implications for immunotherapy approaches
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
JP2016516728A5 (enExample)
Agafina et al. Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)
Han et al. Synergistic integration of HDAC inhibitors and individualized neoantigen therapy (INT): A next-generation combinatorial approach for cancer immunotherapy